Core Insights - 4D Advisors has initiated a new position in U.S. Physical Therapy by acquiring 110,000 shares valued at $9.34 million as of September 30, 2025, indicating strong confidence in the company despite recent stock price declines [2][11]. Company Overview - U.S. Physical Therapy operates 591 clinics across 39 states, providing outpatient physical therapy and industrial injury prevention services, which include rehabilitation and ergonomic assessments [7][10]. - The company reported trailing twelve months (TTM) revenue of $758.71 million and net income of $36.02 million, with a dividend yield of 2.5% [5][10]. Financial Performance - As of November 14, 2025, U.S. Physical Therapy's stock price was $71.67, reflecting an 18.75% decline over the past year, underperforming the S&P 500 by 32.75 percentage points [3][12]. - Revenue for the first three quarters of 2025 reached $578.3 million, up from $490.9 million in 2024, indicating growth in sales [12]. Investment Position - The new position in U.S. Physical Therapy represents 4.97% of 4D Advisors' 13F reportable assets under management, making it the third largest holding in the fund [3][11]. - The price-to-earnings ratio for U.S. Physical Therapy has decreased from over 85 in Q3 of the previous year to approximately 32 in 2025, suggesting a potentially attractive valuation for investors [13].

Company Overview - Chemed Corporation operates two primary segments: VITAS, which provides hospice and palliative care services, and Roto-Rooter, offering plumbing, drain cleaning, and water restoration solutions [4][5] - The company generates revenue through direct service delivery to patients and customers via company-owned branches, independent contractors, and franchisees [4][5] - Chemed's primary customers include patients requiring end-of-life care and residential or commercial clients needing plumbing and related services across the United States [5] Financial Performance - For the trailing twelve months (TTM), Chemed reported revenue of $2.53 billion and net income of $278.81 million [3] - The company's dividend yield stands at 0.44% as of October 28, 2025 [3] - As of October 28, 2025, Chemed shares were priced at $438.94, reflecting a 27.91% decline over the past year and underperforming the S&P 500 by 45.55 percentage points [2] Recent Developments - Schwartz Investment Counsel reduced its position in Chemed by 28,771 shares, valued at approximately $13.03 million, bringing its stake down to 1.67% of reportable assets from 2.24% in the previous quarter [1][2] - Chemed's stock was demoted from the 11th-largest holding to the 17th place in Schwartz's portfolio by the end of September 2025 [6] - The hospice segment experienced a decline in adjusted EBITDA by 3.8% to $70.4 million, despite a 2.98% year-over-year increase in average revenue per day [8] - The Roto-Rooter segment's revenue grew by 1.1% year over year, but adjusted EBITDA declined by 12.4% [9]